Geode Capital Management
PCVX icon

Geode Capital Management’s Vaxcyte PCVX Stock Holding History

Geode Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$186M Buy
3,201,283
+334,978
+12% +$18.2M 0.01% 759
2025
Q4 		$132M Sell
2,866,305
-17,735
-0.6% -$793K 0.01% 905
2025
Q3 		$104M Sell
2,884,040
-127,100
-4% -$4.21M 0.01% 1047
2025
Q2 		$97.9M Buy
3,011,140
+142,086
+5% +$4.66M 0.01% 1041
2025
Q1 		$108M Buy
2,869,054
+66,166
+2% +$5.29M 0.01% 934
2024
Q4 		$229M Buy
2,802,888
+102,106
+4% +$10.1M 0.02% 589
2024
Q3 		$309M Buy
2,700,782
+259,010
+11% +$23.3M 0.03% 510
2024
Q2 		$184M Buy
2,441,772
+154,397
+7% +$10.5M 0.02% 623
2024
Q1 		$156M Buy
2,287,375
+313,869
+16% +$21.7M 0.01% 693
2023
Q4 		$124M Buy
1,973,506
+98,392
+5% +$5.11M 0.01% 745
2023
Q3 		$95.6M Buy
1,875,114
+189,900
+11% +$9.37M 0.01% 823
2023
Q2 		$84.2M Buy
1,685,214
+355,875
+27% +$16.9M 0.01% 898
2023
Q1 		$49.8M Buy
1,329,339
+77,906
+6% +$3.3M 0.01% 1190
2022
Q4 		$60M Buy
1,251,433
+356,647
+40% +$14M 0.01% 1026
2022
Q3 		$21.5M Buy
894,786
+115,091
+15% +$2.92M ﹤0.01% 1675
2022
Q2 		$17M Buy
779,695
+57,732
+8% +$1.34M ﹤0.01% 1871
2022
Q1 		$17.4M Buy
721,963
+66,246
+10% +$1.45M ﹤0.01% 1987
2021
Q4 		$15.6M Buy
655,717
+25,150
+4% +$585K ﹤0.01% 2128
2021
Q3 		$16M Buy
630,567
+111,593
+22% +$2.7M ﹤0.01% 2114
2021
Q2 		$11.7M Buy
518,974
+98,086
+23% +$2.01M ﹤0.01% 2350
2021
Q1 		$8.31M Buy
420,888
+120,311
+40% +$3.03M ﹤0.01% 2479
2020
Q4 		$7.99M Buy
300,577
+8,164
+3% +$304K ﹤0.01% 2312
2020
Q3 		$14.4M Buy
292,413
+266,887
+1,046% +$10.6M ﹤0.01% 1743
2020
Q2 		$806K Buy
+25,526
New +$821K ﹤0.01% 3210

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management's PCVX Position: Q1 2026 in Review

Geode Capital Management increased its Vaxcyte (PCVX) stake by 12% in Q1 2026, buying an estimated $18.2M and bringing the position to 3,201,283 shares worth $186M. The position accounts for 0.01% of the portfolio, ranked #759.

Geode Capital Management first reported a position in PCVX in Q2 2020 and has held it in 24 quarters since. The position peaked at $309M in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Geode Capital Management held 3,201,283 shares of Vaxcyte worth $186M as of Q1 2026.
  • Geode Capital Management bought 334,978 Vaxcyte shares in Q1 2026, an estimated $18.2M.
  • Vaxcyte made up 0.01% of Geode Capital Management's portfolio in Q1 2026, its #759 holding.
  • Geode Capital Management first reported a position in Vaxcyte in Q2 2020 and has held it in 24 quarters since.
  • Geode Capital Management's Vaxcyte position peaked at $309M in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.